Galaxy Biotech to Regain Worldwide Rights to HuL2G7, a Clinical Stage Humanized Monoclonal Antibody Against HGF for Treatment of Cancer SUNNYVALE, Calif., June 19, 2012 (GLOBE NEWSWIRE) -- Galaxy Biotech, LLC, a biotechnology company focused on developing monoclonal antibodies for the treatment of cancer, announced today that it has...

Geller Biopharm Successfully Advises BELLUS Health in Its KIACTA(TM) Transaction With Celtic Therapeutics NEW YORK, April 30, 2010 (GLOBE NEWSWIRE) -- Geller Biopharm, Inc. announced today that they have successfully advised BELLUS Health of LAVAL, Quebec, Canada in its transaction with Celtic...

Geller Biopharm Advisor to Threshold Pharmaceuticals, Inc.; Threshold Completes $35M PIPE NEW YORK, Oct. 6, 2009 (GLOBE NEWSWIRE) -- Matthew Geller, Ph.D., as a managing director of Reedland Capital Partners, an Institutional Division of Financial West Group, has co-led a $35 million...